Goldman Sachs Injects $20M In China Biotech Firm Ascletis

Login to View

Hangzhou-based biotech firm Ascletis has received US$20 million from Goldman Sachs, bringing the company’s total fundraising to US$55 million, according to a company announcement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in

Join China Money Network for $89 a month